Concert Pharma

CNCE NASDAQ
10.72
-0.21
-1.92%
Opening 10:53 07/19 EDT
Open
10.92
Prev Close
10.93
High
10.94
Low
10.71
Volume
15.26K
Avg Vol (3M)
202.83K
52 Week High
17.86
52 Week Low
9.21
% Turnover
0.06%
Market Cap
255.11M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Concert Pharma CNCE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.
MORE >

Recently

Name
Price
%Change